PropertyValue
?:abstract
  • SARS-CoV-2 is assumed to use angiotensin-converting enzyme 2 (ACE2) and other auxiliary proteins for cell entry Recent studies have described conjunctival congestion in 0 8% of patients with laboratory-confirmed severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), and there has been speculation that SARS-CoV-2 can be transmitted through the conjunctiva However, it is currently unclear whether conjunctival epithelial cells express ACE2 and its cofactors In this study, a total of 38 conjunctival samples from 38 patients, including 12 healthy conjunctivas, 12 melanomas, seven squamous cell carcinomas, and seven papilloma samples, were analyzed using high-throughput RNA sequencing to assess messenger RNA (mRNA) expression of the SARS-CoV-2 receptor ACE2 and its cofactors including TMPRSS2, ANPEP, DPP4, and ENPEP ACE2 protein expression was assessed in eight healthy conjunctival samples using immunohistochemistry Our results show that the SARS-CoV-2 receptor ACE2 is not substantially expressed in conjunctival samples on the mRNA (median: 0 0 transcripts per million [TPM], min: 0 0 TPM, max: 1 7 TPM) and protein levels Similar results were obtained for the transcription of other auxiliary molecules In conclusion, this study finds no evidence for a significant expression of ACE2 and its auxiliary mediators for cell entry in conjunctival samples, making conjunctival infection with SARS-CoV-2 via these mediators unlikely
is ?:annotates of
?:creator
?:journal
  • Journal_of_Medical_Virology
?:license
  • unk
?:publication_isRelatedTo_Disease
is ?:relation_isRelatedTo_publication of
?:source
  • WHO
?:title
  • Expression of the COVID-19 receptor ACE2 in the human conjunctiva. (Special Issue: New coronavirus (2019-nCoV or SARS-CoV-2) and the outbreak of the respiratory illness (COVID-19): part-VI.)
?:type
?:who_covidence_id
  • #935097
?:year
  • 2020

Metadata

Anon_0  
expand all